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Bullous SLE: A Phenotypically Distinctive but
Immunologically Heterogeneous Bullous Disorder
W. Ray Gammon and Robert A. Briggaman
Bullous systemic lupus erythematosus (SLE) is a rare blistering disease with a distinctive combination of clinical, histologic
and immunopathologic features that together constitute a unique bullous disease phenotype. There appear to be at least
two immunologically distinct subtypes of bullous SLE characterized by the presence or absence of circulating and/or tissue-
bound basement membrane zone autoantibodies that recognize type VII collagen. The two subtypes are not clearly
distinguishable except by indirect immunofluorescence and/or direct immunoelectron microscopy. In patients without
circulating antibodies, immunoelectron microscopy is required to distinguish between the two subtypes. Patients with
autoantibodies to type VII collagen are similar but not identical to patients with epidermolysis bullosa acquisita – another
bullous disease associated with autoantibodies to type VII collagen. Autoantibodies to type VII collagen in patients with
bullous SLE is only one of several lines of evidence that indicate autoimmunity to that protein and susceptibility to SLE are
associated phenomena. In addition, there is emerging evidence for an association between epidermolysis bullous acquisita
and SLE. There is also evidence that autoantibodies to type VII collagen are pathogenic in bullous SLE (and epidermolysis
bullosa acquisita) and that their production is regulated by the class II major histocompatibility complex DR beta 1 allele,
1501 and possibly other DR beta 1 alleles that share a similar sequence of amino acids in the second hypervariable region.
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During the past 20 years, there have been reports of a small number of
patients with systemic lupus erythematosus (SLE) who developed a
blistering disorder with a relatively distinctive combination of clinical,
histologic, immunohistologic and immunoelectron microscopic (IEM)
features [1–16]. Those features include a widespread eruption of vesicles
and bullae that often respond to treatment with dapsone; dermal-
epidermal separation at the epithelial basement membrane zone (BMZ)
and acute inflammation similar to that seen in dermatitis herpetiformis
(DH); a linear, granular, or mixed linear and granular pattern of
immunoglobulin (Ig) (IgG, IgM, IgA) deposits at the BMZ by direct
immunofluorescence (DIF); and Ig deposits in the upper dermis and on
the lamina densa by IEM. This combination of features is not
characteristic of any other primary bullous disease nor is it generally
seen except in patients with SLE. The distinctiveness of the phenotype
and its association with SLE support the view that it is a specific
manifestation of SLE. It is usually referred to as bullous eruption of SLE or,
simply, bullous SLE.
In our experience, most patients with the bullous SLE phenotype and
linear or mixed linear and granular Ig deposits have autoantibodies to the
BMZ protein, type VII collagen. We refer to those patients as type I
bullous SLE (bullous SLE-I). The antibodies may be circulating and tissue-
bound, or just tissue-bound. In the former case, circulating antibodies
can be detected by indirect immunofluorescence (IIF) but in the latter the
tissue-bound antibodies can only be detected by IEM. Importantly, the
absence of circulating antibodies to type VII collagen does not define a
subset of ‘‘bullous SLE patients without BMZ antibodies’’ because the
antibodies in those patients may be tissue-bound.
Antibodies to type VII collagen are not present in all patients. In some
cases, circulating antibodies to the BMZ cannot be detected by IIF, and
the Ig deposits in the upper dermis do not codistribute with type VII
collagen by IEM. We refer to those patients as type II bullous SLE (bullous
SLE-II). With the exception of antibodies to type VII collagen, it is not
clear that bullous SLE I and II are distinguishable. It is certainly not
confirmed that differences in the pattern of Ig deposits by DIF can identify
either type, and it is equally clear that negative IIF does not exclude
bullous SLE-I. Consequently, we believe that in those cases where
circulating antibodies to type VII collagen cannot be demonstrated by IIF,
IEM is required to distinguish between bullous SLE I and II.
Several lines of evidence indicate that autoimmunity to type VII
collagen and SLE are associated phenomena and that antibodies to type
VII collagen may be part of the autoantibody repertoire of SLE. The
evidence includes (1) antibodies to type VII collagen in bullous SLE; (2)
an apparent association between susceptibility to SLE and another
disease associated with autoimmunity to type VII collagen, epidermolysis
bullosa acquisita (EBA); and (3) indications that antibodies to type VII
collagen may be present in LE in the absence of a blistering eruption.
Experimental evidence indicates that antibodies to type VII collagen
may play a role in BMZ inflammation and injury in bullous SLE and EBA,
but there is much that is unknown about the pathogenesis of these
diseases. It is not clear why patients develop autoimmunity to this major
BMZ adherence protein, but susceptibility is determined, in part, by
genetic factors because patients with bullous SLE-I and epidermolysis
bullosa acquisita (EBA) share some of the same class II MHC genes.
THE BULLOUS SLE PHENOTYPE: FEATURES AND
DIAGNOSTIC CRITERIA
Clinical Features The bullous SLE phenotype is composed of a
characteristic set of clinical, histologic, immunohistologic (DIF), and
IEM features that develop in a patient who meets the American
Rheumatism Association’s (ARA) classification criteria for SLE [4,5,13].
Most patients have been young black women, but all ages, races, and
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both sexes are affected [1–16]. The clinical features include a wide-
spread, non-scarring vesiculobullous eruption that may occur on, but is
not confined to, sun-exposed skin. Lesions may involve flexural or
extensor skin and mucosal surfaces of the mouth and pharynx. A
predilection for the upper trunk and supraclavicular sites has been
described (Fig 1). Blisters usually arise on erythematous (inflamed) skin
and erythematous macules and plaques may precede blisters. Blisters
may be large and tense and resemble those of bullous pemphigoid (BP) or
small and grouped and resemble those of dermatitis herpetiformis (DH).
Mechanical fragility of the skin and healing with scars and milia,
characteristic features of classic EBA, are not features of bullous SLE.
Pruritus is not prominent, but patients may itch and the itching may be
severe. The activity of the blistering disorder may or may not coincide
with the activity of the patient’s systemic disease [4], Interestingly, the
primary lesions of chronic discoid, subacute, and acute LE appear to be
uncommon in bullous SLE.
An important and interesting clinical feature of bullous SLE is that it
may respond to treatment with dapsone [4,6–8,12–14,16]. The response
is usually dramatic, with cessation of new lesions within 24–48h after
administering the drug, and healing of old lesions within several days. A
response may be seen with very small doses (25–0mg/d). Rapid
recurrences may follow cessation of dapsone and rapid remissions may
be achieved after reinstituting the drug. These observations persuasively
argue for a therapeutic effect of dapsone. The rapid and complete
response observed to relatively small doses of dapsone is reminiscent of
the response observed in DH. Eventually it is possible to discontinue
administration of dapsone in bullous SLE without a recurrence of the
blistering eruption; however, DH will rapidly exacerbate after with-
drawal of dapsone. Not all patients with bullous SLE respond to dapsone;
therefore, non-responsiveness does not exclude the diagnosis. Patients
not responding to dapsone may respond to prednisone or combination
therapy with prednisone and azathioprine [2,3,5,9,10,13].
Histologic Features The histologic features of early blisters have been
one of the most consistent and characteristic features of the disease.
Typically, the histology of an early lesion shows inflammation and
dermal-epidermal separation at the BMZ (Fig 2). The epidermis is usually
intact. The upper dermis is characterized by edema and accumulations of
neutrophils in dermal papillae similar to those seen in DH [2,4]. In many
cases, neutrophils are not confined to the papillae but form a continuous
band of cells that is concentrated in the upper dermis, beneath and on the
BMZ, and in the blister cavity. Some mononuclear cells and eosinophils
are usually present in the infiltrate. Mid and upper dermal blood vessels
may have a perivascular accumulation of mononuclear or polymor-
phonuclear cells; and, in some cases, the histologic features of
necrotizing vasculitis including leukocytoclasis, erythrocyte extravasa-
tion, and necrosis of blood vessels are apparent [4]. Dermal vasculitis is
not always present in bullous SLE but may be more common than in DH
[4]. Although vasculitis may be present histologically, clinical features of
vasculitis such as necrosis and palpable purpura are absent. Histologic
changes characteristic of primary lupus lesions such as epidermal
atrophy, basal keratinocyte vacuolization, thickening of the BMZ, and
mononuclear cell-predominant inflammation are absent in bullous
lesions.
Immunohistologic Features Immune deposits in the upper dermis and on
the BMZ are a consistent feature of bullous SLE. Occasionally, deposits
may also be in upper dermal venules. The deposits have been detected
by DIF in lesional skin in all patients and in clinically normal skin in all
but one patient. The composition of the deposits has included all the
major Ig classes (IgG, IgA, and IgM), and complement (C) proteins. In
most cases more than one Ig class is present and in many cases all three
can be detected. IgG has been universally present, IgA has been detected
in most patients, and IgM has been found in about half the patients
[4,13,14]. Complement proteins are usually present in lesional skin but
may be absent in clinically normal skin (personal observation). Unlike
DH, patients with bullous SLE may lack IgA deposits at the BMZ;
however, IgA deposits appear to be more comon in bullous SLE than in
SLE patients without blisters [4,13].
One of the most variable features of bullous SLE is the pattern of
immune reactant deposition. Two major patterns have been described
[4,6,8] (Fig 3). In most patients the pattern is either granular (about 60%
of cases) or linear (about 40% of cases). In a few cases, it has been
thready or fibrillar. In some cases, there may be a mixed pattern with a
linear band of homogeneous deposits and scattered granular deposits.
Among patients with a linear pattern, the deposits may be wide and
bandlike or relatively thin. Granular IgA deposits confined to dermal
papillae, a characteristic feature of DH, are not a feature of bullous SLE
Figure 1. Vesiculobullous lesions on the neck and upper chest in a patient
with bullous SLE.
Figure 2. Histologic features of early lesions of bullous SLE showing
neutrophils (arrows) beneath the BMZ in dermal papillae. A, a patient with
bullous SLE-I who had antibodies to type VII collagen; B, a patient with
bullous SLE-II who apparently lacked antibodies to type VII collagen.
Magnification  180.
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[4]. Importantly, the clinical and histologic features of the bullous SLE
phenotype are similar regardless of the pattern of Ig deposits.
IEM studies have shown the Ig deposits are located in the upper
dermis beneath the lamina densa, and, in some cases, on the
lamina densa [3,4,7,8] (Fig 4). Occasionally, the deposits may be on
andjust beneath the lamina densa and in the deeper dermis as well. The
deposits are not in the lamina lucida, and that excludes the possibility the
blisters are due to a primary bullous disease, such as BP, that is
associated with antibodies to hemidesmosomal and/or lamina lucida
antigens.
CRITERIA FOR THE BULLOUS SLE PHENOTYPE AND
EXCLUSION OF OTHER BULLOUS DISEASES
The above clinical, histologic, immunohistologic, and IEM features are
generally regarded as characteristic of the bullous SLE phenotype and
form the basis for the diagnosis (Table I). Minimal features include (1) a
diagnosis of SLE by ARA criteria; (2) an acquired, non-scarring bullous
eruption; (3) a subepidermal blister with acute neu-trophilpredominant
inflammation in the dermis and at the BMZ; and (4) IgG/IgA/IgM deposits
in perilesional skin [4,5,13]. The Ig deposits must be on or beneath the
lamina densa to exclude BP or other primary subepidermal bullous
diseases associated with antibodies to hemidesmosomal or lamina lucida
antigens. It is important to exclude DH because several of its features
resemble bullous SLE, and a number of patients with both disorders have
been reported [17–21]. Some of those may have been patients with
bullous SLE [4,22]. The major differences between DH and bullous SLE
and the problems in differential diagnosis have been noted above and
extensively reviewed [4,22]. The only other primary bullous disease to
consider is EBA and the relationship between EBA and bullous SLE is
discussed below.
AUTOIMMUNITY TO TYPE VII COLLAGEN AND THE
BULLOUS SLE PHENOTYPE: BULLOUS SLE-I
In 1985, IgG autoantibodies to the BMZ of stratified squamous
epithelium were reported in patients with bullous SLE [8]. The antibodies
were initially detected in serum by IIF on substrates of normal human
Figure 3. Direct IgG immunofluorescent microscopy of perilesional skin
from three patients with bullous SLE showing different patterns of IgG deposits
at the BMZ. A, a granular and mixed granular-linear pattern that may be seen
in patients with bullous SLE-I and bullous SLE-II; magnification  240. B,
a wide linear/homogeneous pattern that may be seen in patients with
bullous SLE-I and bullous SLE-II; magnification 240. C, a very narrow
linear band of deposits that may be seen in patients with bullous SLE-I;
magnification  400.
Table I. Tentative Criteria for the Diagnosis of Bullous
SLE
Type I
Clinical: an acquired, widespread, nonscarring vesiculobullous
eruption
Histologic: subepidermal blister and acute, neutrophil-predominant
inflammation in the upper dermis
DIF: IgG±IgA/IgM at the BMZ
IIF: ±circulating autoantibodies to type VII collagen-confirmed by IIF
on split skin, immunoblotting or immunoprecipitation
IEM: Ig deposits codistribute with anchoring fibrils/type VII collagen
Type II
Clinical: same as above
Histologic: same as above
DIF: same as above
IIF: negative
IEM: Ig deposits do not codistribute with anchoring fibrils/type VII
collagen
Figure 4. Direct IgG immunoelectron microscopy of perilesional skin from
a patient with bullous SLE. The IgG deposits (D) are located in the upper
dermis just beneath the lamina densa/basal lamina (B). The lamina lucida (L);
which lies between the keratinocyte plasma membrane and the lamina densa,
is free of deposits. Magnification  18,000.
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skin that had been separated through the BMZ by incubation in 1M NaCl
(Fig 5). Direct IEM on perilesional skin from those cases showed the Ig
deposits were in the upper dermis beneath and on the lamina densa (see
Fig 4). Those IEM findings were consistent with findings previously
reported in bullous SLE (and SLE as well), and excluded the possibility
that the autoantibodies were directed to lamina lucida or hemidesmo-
somal antigens [3,4,8,10,23,24]. The absence of Ig deposits in the lamina
lucida also excluded the possibility the patients had coexistent SLE and
BP, which had been reported [25–31].
The circulating antibodies from those patients were further character-
ized and found to have immunochemical, immunohistologic, and
immunoultrastructural features that are now known to be characteristic
of antibodies to type VII collagen [32]. Those features included reactivity
with 290-kD and 145-kD proteins in extracts of human skin basement
membrane, binding to the dermal side of split skin, and binding on and
just beneath the lamina densa of normal human skin by indirect IEM [8]
(Figs 4–6). The localization of the cutaneous Ig deposits on and just
beneath the lamina densa by direct IEM was also consistent with tissue-
bound antibodies to type VII collagen.
We have also encountered patients in whom IIF studies have been
negative, but direct IEM has shown IgG deposits on and just beneath the
lamina densa in a pattern characteristic of antibodies to type VII collagen
[3]. The deposits in these cases have been indistinguishable from deposits
in patients with circulating antibodies to type VII collagen [32]. Some of
these patients also have scattered Ig deposits in the upper dermis that are
not associated with a specific structure or matrix protein. The latter are
not unlike the deposits described in some SLE patients without a
blistering eruption [33–35]. These observations suggest there are patients
with bullous SLE-I who have tissue-bound, but not circulating, antibodies
to type VII collagen. Furthermore, some of these patients appear to have,
in addition to specific BMZ antibodies, the non-specific Ig deposits often
encountered in SLE.
BULLOUS SLE PHENOTYPE WITHOUT
AUTOANTIBODIES TO TYPE VII COLLAGEN:
BULLOUS SLE-II
Patients with bullous SLE without circulating autoantibodies to type VII
collagen have been reported [3–5,13,14]. Most of them were not
examined by direct IEM; therefore, their status regarding type VII
collagen autoimmunity remains unresolved. However, we know of at
least one case that was completely evaluated using immunofluorescence
and IEM without finding evidence of autoantibodies to type VII collagen.
Briefly, the patient was a 41-year old white woman with SLE diagnosed
on the basis of photosensitivity, arthralgias, a coombsþhemolytic
anemia, a positive antinuclear antibody (ANA) (titer 1:2560), lymphade-
nopathy, and nephritis. She had an 8-month history of a recurrent, non-
scarring vesiculo-bullous eruption of the face, upper chest, back, and
extensor extremities. The lesions cleared within 2 d of treatment with
50mg daily of dapsone. The histology of a skin lesion showed a
subepidermal blister with neutrophil-predominant, DH-like inflamma-
tion (Fig 2B). DIF of perilesional skin showed a mixed linear and granular
pattern of IgG, IgA, and IgM deposits at the BMZ (Fig 3B). IIF on NaCl
split skin showed no evidence of BMZ antibodies even in undiluted
serum. Direct IEM showed scattered granular deposits of IgG, IgA, and
Figure 5. Indirect IgG immunoflurescent microscopy on 1.0M NaCl-split skin
using a 1:10 dilution of serum from a patient with bullous SLE-I. The
photomicrograph shows a linear band of IgG on the dermal side of the split
(lower portion of the photograph) consistent with antibodies to type VII
collagen. There are also deposits on the nuclei of keratinocytes (upper portion
of the photograph) consistent with antinuclear antibodies. Magnification
240.
Figure 6. Western immunoblotting of type VII collagen extracted from human
basement membrane. Lane 1 shows molecular weight standards. Lane 2
shows blotting with EBA serum containing high titer antibodies to type VII
collagen; the serum is a positive control and shows binding to the 290 kD
band of tissue type VII collagen. Lane 3 shows blotting with serum from a
patient with bullous SLE (BSLE). That serum also shows binding to a 290 kD
band. Lane 4 shows blotting with serum from the Texas rabbit that Nicholes
and Gilliam had immunized with human epithelial basement membrane
extracts. Those investigators showed the immune rabbit serum contained
antibodies that cross-reacted with antibodies from lupus patients against
extracts of basement membrane. Lane 5 shows blotting with normal human
serum as a negative control.
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IgM in the upper dermis but no deposits were observed on or just beneath
the lamina densa where type VII collagen is located (Fig 7). Anchoring
fibrils, which are composed primarily of type VII collagen, were clearly
visible in the immunoelectron micrographs and were not associated with
Ig deposits. This patient clearly had the features of the bullous SLE
phenotype but did not have evidence of antibodies to type VII collagen.
DISTINGUISHING BETWEEN
BULLOUS SLE TYPES I AND II
Evaluating patients with bullous SLE for autoantibodies to type VII
collagen is not easy. Even in cases with circulating antibodies, routine IIF
using epithelial substrates with an intact BMZ may give negative results
[8,16]. The antibodies are usually low titer (o1:10 to 1:40), and there
may be interference from anti-nuclear antibodies. The most sensitive
substrate in our experience is NaCl-split normal human skin [36]. The
substrate also distinguishes between autoantibodies to type VII collagen
and autoantibodies to hemidesmosomal and lamina lucida antigens. In
patients without circulating antibodies, IEM studies, which are expensive
and not always easy to obtain, are required to demonstrate Ig deposits
codistributing with type VII collagen. Unfortunately, the great majority of
patients reported as ‘‘bullous SLE without BMZ autoantibodies’’ have
only been evaluated by IIF and usually by standard IIF rather than IIF on
split skin.
To our knowledge, patients with and without antibodies to type VII
collagen are indistinguishable with the possible exception that the latter
may be more likely to have a granular or mixed granular-linear pattern of
Ig deposits. However, very few patients with a granular pattern have been
examined by IEM, and some of them may have tissue-bound BMZ
antibodies. This possibility is suggested by reports of eluting BMZ
autoantibodies from the skin of SLE patients with granular deposits at the
BMZ [37–39]. It is clear that patients with the bullous SLE phenotype may
have antibodies to type VII collagen, that those antibodies may only be
present in tissue, and that the only reliable way to detect tissue-bound
antibodies (or exclude them) is IEM.
RELATIONSHIP BETWEEN BULLOUS SLE-I AND EBA
The relationship between bullous SLE-I and EBA is an interesting question
that has not been satisfactorily resolved. Clearly, they are closely related
disorders because both are chronic acquired bullous diseases characte-
rized histologically by inflammatory subepidermal blisters and immuno-
logically by circulating and tissue-bound autoantibodies to type VII
collagen. They also appear to share similar genetic features (see below).
Additional evidence supporting a relationship includes the fact that the
clinical and pathologic features characteristic of bullous SLE may
occasionally occur in EBA. For example, EBA may present with a
widespread non-scarring bullous eruption without mechanical fragility
and with a DH-like histology [40]. In addition EBA, like bullous SLE, may
be associated with SLE (see below); and patients with the bullous SLE
phenotype may evolve an EBA phenotype ([41], personal observation).
Nevertheless, there appear to be differences between the characteristic
features of the disorders and some of those differences are clinically
significant. Unlike bullous SLE, EBA is often associated with skin fragility
and healing of lesions with scars and milia. The DH-like histology that is
typical of bullous SLE is seldom seen in EBA. Whereas EBA usually begins
in the fourth and fifth decades, bullous SLE usually begins in the second
and third decades. EBA often lasts for many years whereas bullous
SLE is remitting and often resolves spontaneously in less than a year.
Interestingly and perhaps most importantly, EBA only rarely, if ever,
responds to treatment with dapsone.
RELATIONSHIP BETWEEN SLE AND
AUTOIMMUNITY TO TYPE VII COLLAGEN
Several lines of evidence strongly suggest an association between
susceptibility to LE and autoimmunity to type VII collagen and that
autoantibodies to type VII collagen are part of the autoantibody repertoire
of some patients with LE. One piece of evidence is that autoantibodies to
type VII collagen are present in bullous SLE. Another is the apparent
association between SLE and EBA. Patients have been described with
concurrent SLE and EBA, SLE followed by EBA, and EBA followed by SLE
[41–43]. Of over 60 patients we have seen with autoimmunity to type VII
collagen, approximately 30% have, have had, or develop SLE, which can
hardly be viewed as a coincidental association given the relative
infrequency of the conditions.
Not all patients with SLE and autoantibodies to type VII collagen have
a blistering disease. We have documented at least one patient who had
SLE by ARA criteria and circulating and tissue-bound antibodies to type
VII collagen documented by IIF on split skin, IEM, and immunoblotting
studies [8]. That patient had a circulating, low-titer IgG BMZ autoanti-
body in serum that bound exclusively to the dermal side of split skin. By
direct IEM, there were IgG deposits codistributing with type VII collagen
and Western immunoblotting showed a serum antibody that reacted with
290- and 145-kD bands in extracts of human BMZ. The patient had no
history of a blistering eruption, and never developed blisters during an
8-year follow-up. That is the only patient we have encountered with SLE
without a blistering eruption in whom we have found direct evidence for
autoantibodies to type VII collagen. We have not found the antibodies
among 30 additional SLE patients using IIF on split skin. However, those
studies do not exclude the possibilities of tissue-bound antibodies
without circulating antibodies, as in some patients with EBA and bullous
SLE, or that circulating antibodies are present in insufficient concentra-
tion to be detected by IIF.
There are also several indirect lines of evidence suggesting antibodies
to type VII collagen may be present in LE patients without a blistering
eruption. One is the IEM features of cutaneous Ig deposits in SLE patients
without a blistering eruption. Several studies have reported and shown
illustrations of IgG deposits that are indistinguishable from the deposits in
EBA and bullous SLE patients with antibodies to type VII collagen
[23,24].
Additional evidence for BMZ autoantibodies in SLE comes from a
group of three studies, which collectively investigated the specificity of
antibodies in eluates of cutaneous Ig deposits in several SLE patients
[37–39]. The results showed most of those eluates contained IgG
antibodies that reacted with the BMZ of normal human skin. The
specificity of those antibodies has not been determined but the studies
suggest elution of tissue-bound Ig might be a reasonable approach to
investigate a possible association between autoanti-bodies to type VII
collagen and SLE.
Figure 7. IgG direct immunoelectron microscopy (magnification  15,000)
comparing the pattern of IgG deposits at the BMZ in A, a patient with bullous
SLE-I who has antibodies to type VII collagen and B, a patient with bullous
SLE-II who apparently does not have those antibodies. A shows deposits on
and just beneath the lamina densa and codistributing with type VII collagen.
Similar deposits can also be seen in Fig 4. B shows deposits (D) in the upper
dermis but well beneath the lamina densa. The deposits do not codistribute
with anchoring fibrils (arrows), which are distinctly separate from the
deposits.
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Additional evidence for BMZ autoantibodies (some of which
may have anti-type VII collagen specificity) comes from studies by the
late Dr. James N. Gilliam and his co-worker, Dr. Brenda Nicholes
[44,45]. They tested sera from a number of SLE patients and controls
for antibodies to antigens in extracts of normal human skin BMZ using
a sensitive counter immunoelectrophoresis assay. They found that 30
percent of LE patients, but no controls, had antibodies to the extracts.
Rabbits immunized with the extracts produced antibodies that
reacted to a lamina densa antigen in normal human skin. Gilliam and
Nicholes found that immune rabbit serum and serum from one of the SLE
patients had antibodies that cross-reacted with human BMZ antigens.
Shortly before his death, Dr. Gilliam sent immune rabbit serum to one
of us (WRG), and analysis of that serum by IIF on split skin and
immunoblotting against extracts of human BMZ showed it contained
antibodies to human type VII collagen (Fig 6). The observations made by
Gilliam and Nicholes clearly raise the possibility that BMZ antibodies
may not be rare in SLE, and that they may, in some cases, react with type
VII collagen.
GENETIC REGULATION OF AUTOIMMUNITY
TO TYPE VII COLLAGEN IN BULLOUS SLE-I
During the past several years, we have been investigating an association
between major histocompatibility complex (MHC) genes and autoimmu-
nity to type VII collagen. In an initial study, we typed class I and class II
MHC antigens in a large number of white and black EBA patients and a
small number (6) of black patients with bullous SLE-I [46]. The results of
those studies showed a significant association between the class II
antigen, DR2, and EBA in both white and black patients. Furthermore, we
found that five of six patients with bullous SLE were DR2 positive. We
have recently completed class II MHC typing on an additional 12 patients
with bullous SLE and found a 76% incidence of DR2 among the
combined 18 patients, which is significantly greater than the incidence of
DR2 in geographic and race-matched controls. It seems unlikely that the
DR2 association is due to an independent association with SLE because
all but 1 of the 18 patients is black and studies of blacks with SLE have
failed to demonstrate an association with DR2 [47–49]. We have recently
sequenced the hypervariable region of the DR beta 1 gene from several
DR2-positive bullous SLE (and EBA) patients and found they all have the
DRB1 1501 allele [50].
The results of our studies show that the DR beta 1 gene and
specifically the DRB1 1501 allele are associated with autoimmunity to
type VII collagen in both EBA and bullous SLE. The results suggest that
gene may be involved in regulating susceptibility to type VII collagen
autoimmunity. One of the major functions of the proteins encoded by DR
genes is to complex with fragments of proteins antigens on the surface of
antigen-presenting cells and present the antigens to specific T cells. The
associations we have observed in EBA and bullous SLE suggest that the
antigen-presenting protein encoded by the DRB1 1501 allele may
(because of its unique amino acid sequence) be involved directly in
presenting type VII collagen epitopes or epitopes that mimic type VII
collagen to specific T cells. That hypothesis is supported by preliminary
evidence indicating that the association between DR and autoimmunity
to type VII collagen maps to the second hypervariable region of DR beta
1 proteins [50]. It is clear that not all patients with EBA or bullous SLE
carry the DR2 phenotype, suggesting that either other DR beta 1 alleles or
perhaps other MHC genes may also be capable of presenting type VII
collagen epitopes to specific T cells. In fact, evidence that other DR beta
1 alleles may be involved has been obtained [50]. Studies to characterize
those alleles and interactions with type VII collagen epitopes are in
progress.
PATHOGENESIS OF BULLOUS SLE
As indicated above, bullous SLE consists of at least two immunologi-cally
distinct subsets. One is associated with autoantibodies to type VII
collagen and the other appears not to be. Blisters in both subsets appear
to result, at least in part, from inflammatory injury to the BMZ; however,
the cause of inflammation is not established and may be different in
patients with and without antibodies to type VII collagen. There are
several reasons to believe that BMZ immune deposits may play a role in
both subsets. First, all patients have the deposits in perilesional skin.
Second, the deposits are located in the upper dermis on and just beneath
the lamina densa, which corresponds precisely to the ultrastructural
location of BMZ separation. Third, it appears that the site of separation in
the BMZ is specifically targeted for inflammatory injury because it is
normally the strongest region of epidermal-dermal adherence and the
most resistant to separation. The immune deposits are strategically
located to initiate and target that inflammation and currently no other
candidates are known. Fourth, there is evidence the deposits may be able
to initiate inflammation. Studies have shown they are able to activate the
C-system and mediate C-dependent migration and adherence of
leukocytes to the BMZ. Furthermore, cutaneous immune deposits in
the perilesional skin of patients with bullous SLE activate C and generate
C-derived inflammatory mediators to a significantly greater degree than
the deposits in uninvolved skin from the same patients or the deposits in
SLE patients without blisters [6].
There is indirect evidence supporting a specific role for auto-
antibodies to type VII collagen in initiating and targeting inflam-
mation at the BMZ in bullous SLE-1. For example, in vitro studies have
shown the antibodies are capable of activating C and generating
C-derived peptides that can mediate leukocyte activation, migration,
and adherence to the BMZ [51,52]. In addition, they can cause BMZ
disruption and dermal-epidermal separation following passive transfer
in human skin organ culture. Monoclonal antibodies to type VII collagen
have been shown to cause inflammation at the BMZ following
passive transfer in rabbits [53]. Additional indirect evidence comes from
studies showing EBA patients with acute inflammation have significantly
higher levels of circulating and tissue-bound C-activating antibodies
to type VII collagen than EBA patients with chronic or minimal
inflammation [54].
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